Edgewise Receives Fast Track Designation for EDG-5506 in Patients with Becker muscular dystrophy
Edgewise Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for…Learn More
